No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.

Francisca-Dora CopilClaudia CampaniMarie LequoyPhilippe SultanikLorraine BlaiseMathilde WagnerNathalie Ganne-CarriéViolaine OzenneDominique Thabut Jean Charles NaultVlad RatziuManon Allaire

Published in: Liver international : official journal of the International Association for the Study of the Liver (2024)

Our study suggests that the presence of MASLD or the number of MRF did not lead to worse outcomes in advanced HCC patients treated with AtezoBev.

Keyphrases

stem cells
type diabetes
cell therapy